All Children’s Hospital Selects ValiMed™ System for
Medication Validation
Developed by CDEX, the ValiMed System was chosen by All Children’s to Verify Compounded Medications and Doses, and Validate Narcotic Returns
ROCKVILLE, MD-- March 14, 2006 – CDEX Inc., announced today that All Children’s Hospital in St. Petersburg, Florida has selected the ValiMed Medication Validation System to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed System, developed by CDEX (CEXI.OB), gives clinicians a quick, cost- effective, and simple tool to ensure medication safety by verifying medications are correctly compounded. All Children’s Hospital, a 216-bed teaching hospital affiliated with the University of South Florida College of Medicine, is a leading center for pediatric treatment, education, and research.
In a process that takes only seconds, the ValiMed System uses patent-pending technology to validate compounded doses of high-risk medications prior to dispensing. The system documents the accuracy of the medication dispensing process, and is used to validate narcotic returns as well as identify counterfeit medications.
"We are pleased that a nationally recognized institution, such as All Children’s Hospital of Florida, is now using our ValiMed System for medication validation,” said Jim Griffin, President and CEO of CDEX.
The ValiMed System uses light energy and a library of unique spectral fingerprints to validate drugs in a solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation of Englewood, Colorado.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
